TRPV4 and Insulin resistance: TRPV4 agonists promote vasorelaxation and improve cardiovascular function in a rodent type 2 diabetes model, and TRPV4 antagonists reduce high-fat diet-induced obesity, insulin resistance, and diabetes-related complications (Hu et al., 2020), suggesting its potential as a therapeutic target for such diseases.